Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234303 | 0.88 | SIGMAR1 (0.35) | TEAD1SIGMAR1KMT2ASLC6A12 | |
| SCHEMBL3230582 | 0.82 | CCR1 (0.35) | SIGMAR1POLB | |
| SCHEMBL3231946 | 0.74 | UBE2M (0.32) | — | |
| SCHEMBL3148857 | 0.63 | SLC2A1 (0.43) | SIGMAR1SLC6A12 | |
| SCHEMBL3155543 | 0.63 | SLC2A1 (0.54) | SIGMAR1 | |
| SCHEMBL6312739 | 0.63 | SIGMAR1 (0.76) | SIGMAR1MEN1KMT2ASLC6A12 | |
| SCHEMBL3141765 | 0.62 | SLC2A1 (0.42) | SIGMAR1SLC6A12 | |
| SCHEMBL3590338 | 0.61 | SIGMAR1 (0.73) | TEAD1SIGMAR1MEN1KMT2APOLB | |
| SCHEMBL3145888 | 0.61 | SLC2A1 (0.42) | SIGMAR1SLC6A12 | |
| SCHEMBL4909423 | 0.61 | CCR1 (0.50) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | TEAD1 1224/4885SIGMAR1 380/4885MEN1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.